Molecule News and Research

RSS

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.

31 Oct 2009

NeoStem completes acquisition of China Biopharmaceuticals Holdings

NeoStem, Inc., announced today that the Company has completed the acquisition of China Biopharmaceuticals Holdings, Inc., a leading Chinese pharmaceutical company.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Veeva CRM to be implemented at Adamas Pharmaceuticals

Adamas Pharmaceuticals, an emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, selected Veeva System’s VBioPharma™ KOL Edition – part of the Veeva CRM suite. Selection of Veeva’s SaaS solution marks an important step in Adamas’ early-stage product commercialization strategy.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Rutgers scientist receives 2009 Gruber International Research Award

For the first time, it now is possible for researchers to peer into those internal processes in a rodent brain. Eva Pastalkova, a post-doctoral researcher at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark and her advisor, Professor Gy-rgy Buzsaki, have developed a method for studying internally generated brain activity in rats.

28 Oct 2009

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Scientists here have identified how the motions of an enzyme are related to correctly copying genetic instructions, setting the stage for studies that can uncover what happens when DNA copying mistakes are made.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.

27 Oct 2009

Arizona State University researchers to use laws of physics for cancer research

Instead of killing cancer cells, researchers at Arizona State University will use the laws of physics to figure out how to control them. And, rather than treating cancer as a disease and seeking a cure, ASU scientists will view cancer cells as physical objects and study them the way a physicist would, using simple variables like temperature, pressure and force.

27 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

Molecule News and Research

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

NeoStem completes acquisition of China Biopharmaceuticals Holdings

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

New state-of-the-art biotechnology center opened on the West Coast

Study: HSP inhibitor could stop tumor formation and extend survival

Genetic mutations may put individuals at increased risk for fungal infections

Repros Therapeutics amends its existing license for Proellex

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Veeva CRM to be implemented at Adamas Pharmaceuticals

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

Rutgers scientist receives 2009 Gruber International Research Award

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Starting Grant from ERC to LMU junior researchers

Helicos Biosciences reports operational highlights for the third quarter of 2009

Arizona State University researchers to use laws of physics for cancer research

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

Protein crucial for insulin regulation may play a role in diabetes

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News